# A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence

> **NCT07009470** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 130 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar)
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT07009470
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-10
- **Primary completion:** 2028-04-28
- **Final completion:** 2028-10-28
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009470, "A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07009470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*